<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01150747</url>
  </required_header>
  <id_info>
    <org_study_id>PRO10010159</org_study_id>
    <secondary_id>U19AI084024</secondary_id>
    <nct_id>NCT01150747</nct_id>
  </id_info>
  <brief_title>Chlamydia Trachomatis Immunology and Vaccinology Study</brief_title>
  <official_title>Chlamydia Trachomatis Immunology and Vaccinology Study: Determination of Protective T Cell Responses to Chlamydia Trachomatis Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harold Wiesenfeld</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to prospectively follow 200 women with or at risk of cervicitis to&#xD;
      determine the chlamydia-specific cellular responses that correlate with protection against&#xD;
      incident infection. The hypothesis is that a positive IFN-y response by peripheral CD4+ T&#xD;
      cells responding to stimulation with HSP60 will be significantly associated with protection&#xD;
      from incident C. trachomatis infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 200 women with or at high risk of having cervicitis will be prospectively followed&#xD;
      for correlations between chlamydia-specific cellular responses and protection against&#xD;
      incident infection.&#xD;
&#xD;
      At enrollment participants will undergo a history and physical examination; blood draw; and&#xD;
      pelvic examination including collection of vaginal and cervical samples, STD testing and&#xD;
      endometrial biopsy.&#xD;
&#xD;
      Participants will have follow up visits conducted at 1, 4, 8 and 12 months following&#xD;
      enrollment. At the follow-up visits, participants will undergo a repeat history and physical,&#xD;
      blood draw and pelvic examination including collection of vaginal and cervical samples and&#xD;
      STD testing.&#xD;
&#xD;
      The study design will allow comprehensive identification of the antigen-specific cell&#xD;
      mediated immune responses most strongly associated with protection against C. trachomatis&#xD;
      infection.&#xD;
&#xD;
      The primary objective is to prospectively follow 200 women with or at risk for cervicitis to&#xD;
      determine the chlamydia-specific cellular responses that correlate with protection against&#xD;
      incident infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the chlamydia-specific cellular responses that correlates with protection against incident infection</measure>
    <time_frame>one year per patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify immunologic correlates associated with containment of the organism to the lower genital tract</measure>
    <time_frame>one year per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare chlamydia-specific cellular responses in the PBMCs to endometrial lymphocytes</measure>
    <time_frame>one year per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the endocervical T cell phenotypes of women with containment of the organism to the lower genital tract</measure>
    <time_frame>one year per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize transcriptional inflammatory responses of women with Chlamydia</measure>
    <time_frame>Study participation one year per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use SNP analysis to identify genetic risk factors for chlamydia infection and disease</measure>
    <time_frame>Study participation is one year per patient</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">347</enrollment>
  <condition>Chlamydia</condition>
  <arm_group>
    <arm_group_label>Risk of positive chlamydia</arm_group_label>
    <description>current, untreated endocervical C. trachomatis infection&#xD;
mucopurulent cervicitis on pelvic examination&#xD;
Sexual contact with a male partner recently diagnosed with C. trachomatis, and/or non-gonococcal urethritis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone</intervention_name>
    <description>250mg IM once</description>
    <arm_group_label>Risk of positive chlamydia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>1 gm once</description>
    <arm_group_label>Risk of positive chlamydia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women positive for chlamydia or at high risk of chlamydia infection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Women 15-35 years of age. Note: Minors must have written informed consent from her&#xD;
             parent/legal guardian to participate.&#xD;
&#xD;
          2. At least one of the following:&#xD;
&#xD;
               1. Current , untreated endocervical C. trachomatis infection.&#xD;
&#xD;
               2. Mucopurulent cervicitis: defined by the presence of yellow or green endocervical&#xD;
                  mucopurulent discharge and/ or easily induced endocervical bleeding (bleeding&#xD;
                  when the first swab is placed in the endocervix).&#xD;
&#xD;
               3. Sexual contact with a male partner (regardless of condom use) recently diagnosed&#xD;
                  (within the past 3 months) with C. trachomatis and/or non-gonococcal urethritis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing a baby. Note: a urine pregnancy test will be done at enrollment.&#xD;
             Result must be negative to participate in the study.&#xD;
&#xD;
          2. Gynecologic surgery or surgical abortion in preceding 2 months of enrollment.&#xD;
&#xD;
          3. Allergy to any of the study medications and/or derivatives (cephalosporins,&#xD;
             azithromycin, erythromycin, any macrolide or ketolide antibiotic) or Type 1&#xD;
             hypersensitivity allergic reaction to penicillin.&#xD;
&#xD;
          4. Systemic or vaginal antibiotic therapy in preceding 7 days of enrollment.&#xD;
&#xD;
          5. Prior hysterectomy.&#xD;
&#xD;
          6. Menopause.&#xD;
&#xD;
          7. Any condition, in the opinion of the investigator that would interfere with the&#xD;
             participant's safety or with study outcomes.&#xD;
&#xD;
          8. Participation in any study involving an investigational product in the past 30 days or&#xD;
             anticipation of participation in any study using an investigational product in the&#xD;
             next 30 days.&#xD;
&#xD;
          9. Previous participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toni Darville, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allegheny County Sexually Transmitted Disease Clinic</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee-Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>June 23, 2010</study_first_submitted>
  <study_first_submitted_qc>June 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Harold Wiesenfeld</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlamydia Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

